Suppr超能文献

用于低风险骨髓增生异常综合征的患者报告结局的内容效度。

Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes.

作者信息

Trudeau Jeremiah J, He Jianming, Rose Esther, Panter Charlotte, Randhawa Sharan, Gater Adam

机构信息

Janssen Global Services LLC, 700 US 202 South, Raritan, NJ, 08869, USA.

Janssen Pharmaceuticals LLC, Raritan, NJ, 08869, USA.

出版信息

J Patient Rep Outcomes. 2020 Aug 26;4(1):69. doi: 10.1186/s41687-020-00235-4.

Abstract

BACKGROUND

The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients' health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients' HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible. The present study was conducted to evaluate the content validity of the Quality of Life in Myelodysplasia Scale (QUALMS) and the Functional Assessment of Cancer Therapy-Anemia (FACT-An) PRO instruments in patients with lower-risk MDS.

METHODS

In this cross-sectional, qualitative study, 16 patients aged ≥18 years with lower-risk MDS, who were RBC transfusion dependent, literate and fluent in US-English were interviewed. Interviews were semi-structured comprising of two parts: concept elicitation (CE) explored symptoms and impacts important to patients, and cognitive debriefing (CD) assessed understanding and relevance of the QUALMS and FACT-An. A conceptual model was developed, which was used to map the concepts that emerged during CE onto the QUALMS and FACT-An to assess concept coverage and suitability of the instruments.

RESULTS

The median age of participants was 67.5 years (range: 51-91), with half being female (n = 8). Nine (56.2%) participants had intermediate-1-risk MDS and 10 (62.5%) were relapsed or refractory to erythropoiesis-stimulating agent treatment. Fatigue/tiredness (100.0%), shortness of breath (87.5%), weakness (81.2%), and low energy (75.0%) were reported most commonly and were the most bothersome symptoms as well. Of seven high-level HRQoL domains identified, activities of daily living (n = 16, 100.0%), physical functioning (n = 15, 93.8%), emotional wellbeing (n = 13, 81.3%), social functioning (n = 12, 75.0%), sleep disturbance (n = 9, 56.3%), and impact on work (n = 9, 56.3%) were the most commonly reported. For CD, the QUALMS and FACT-An were found to be mostly relevant and very well understood; response options were easy to use, and recall period was appropriate.

CONCLUSION

Both QUALMS and FACT-An demonstrated a strong face and content validity in patients with lower-risk MDS, suggesting that these instruments are appropriate for assessing HRQoL in this population.

摘要

背景

低风险(基于国际预后评分系统的低危和中危 - 1风险)骨髓增生异常综合征(MDS)对患者的健康相关生活质量(HRQoL)有负面影响。用于收集患者HRQoL数据的患者报告结局(PROs)工具,应在目标人群中建立内容效度,以确保该工具全面且易于理解。本研究旨在评估骨髓增生异常综合征生活质量量表(QUALMS)和癌症治疗功能评估 - 贫血量表(FACT - An)这两种PRO工具在低风险MDS患者中的内容效度。

方法

在这项横断面定性研究中,对16名年龄≥18岁、依赖红细胞输血、识字且能流利使用美式英语的低风险MDS患者进行了访谈。访谈采用半结构化,包括两个部分:概念引出(CE)探讨对患者重要的症状和影响,认知反馈(CD)评估QUALMS和FACT - An的理解度和相关性。开发了一个概念模型,用于将CE过程中出现的概念映射到QUALMS和FACT - An上,以评估工具的概念覆盖范围和适用性。

结果

参与者的中位年龄为67.5岁(范围:51 - 91岁),一半为女性(n = 8)。9名(56.2%)参与者患有中危 - 1风险MDS,10名(62.5%)对促红细胞生成素治疗复发或难治。最常报告的症状是疲劳/疲倦(100.0%)、呼吸急促(87.5%)、虚弱(81.2%)和精力不足(75.0%),也是最困扰的症状。在确定的七个高层次HRQoL领域中,日常生活活动(n = 16,100.0%)、身体功能(n = 15,93.8%)、情绪健康(n = 13,81.3%)、社会功能(n = 12,75.0%)、睡眠障碍(n = 9,56.3%)和对工作的影响(n = 9,56.3%)是最常报告的。对于CD,发现QUALMS和FACT - An大多相关且理解良好;回答选项易于使用,回忆期合适。

结论

QUALMS和FACT - An在低风险MDS患者中均表现出较强的表面效度和内容效度,表明这些工具适用于评估该人群的HRQoL。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/058f/7450032/25030b105ca9/41687_2020_235_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验